Key findings on prostate cancer treatment from the 2025 ASCO meeting are reported by Dr Oliver Sartor from Tulane Medical School in New Orleans.

Dr Sartor begins by highlighting the phase 3 AMPLITUDE trial, which evaluated niraparib (NIRA) combined with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer. The risk for radiographic progression or death was reduced by 37% using the combination of NIRA plus AAP compared with placebo plus AAP.

Next, Dr Sartor discusses a phase 1/2 study of terbium-161, a novel radionuclide that may improve the targeting of micrometastases. The radioligand therapy displayed highly encouraging efficacy and few grade 3 or 4 adverse events. An additional cohort to assess a higher administered radioactivity is planned.

Dr Sartor also reports results from a phase 2 trial looking at baseline prognostic value of PSMA-PET total tumor volume (TTV) and PSMA-PET standardized uptake value (SUV) in the ENZA-p trial of enzalutamide (ENZA) vs enzalutamide plus [¹⁷⁷Lu] Lu-PSMA-617 (LuPSMA).

Baseline PSMA-TTV was prognostic of shorter overall survival for ENZA alone but not for ENZA plus LuPSMA. Individuals with the lower PSMA-PET uptake did much better with enzalutamide than those with a high PSMA-PET uptake.

Finally, Dr Sartor examines early data on KLK2 as a novel target amenable to T-cell redirection. The data will be reviewed further in larger, phase 3 studies.